Aug 2026· Journal of Alzheimer's Disease· Vol 113, pp. 1420 - 1439· 0 citations· 59 references
Medicine
TL;DR
CSF NDRG2 levels were significantly reduced in MCI, most prominently in non-Aβ and non-tau subgroups, and NDRG2 levels were positively correlated with GAP-43, a marker of synaptic plasticity.
Abstract
Background Mild cognitive impairment (MCI) lacks clear clinical biomarkers. N-Myc downstream-regulated gene 2 (NDRG2) is predominantly localized in astrocytes and is implicated in cognitive function. Objective This study aims to explore whether cerebrospinal fluid (CSF) NDRG2 could predict MCI and investigate its underlying mechanisms of cognitive decline. Methods A total of 650 CSF samples were collected from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, comprising 157 normal individuals, 366 MCI patients, and 127 Alzheimer's disease (AD) patients. One-way analysis of covariance (ANCOVA) was employed to assess differences in CSF NDRG2 levels among groups. Linear regression was used to analyze the correlation between NDRG2 and amyloid-β (Aβ), phosphorylated tau (p-tau), 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), albumin quotient (Qalb), and growth-associated protein 43 (GAP43). Receiver operating characteristic (ROC) curves were used to examine the diagnostic performance of NDRG2 for MCI. Results CSF NDRG2 levels were significantly reduced in MCI, most prominently in non-Aβ and non-tau subgroups. NDRG2 discriminated Aβ-negative MCI with an area under the curve (AUC) of 0.719, but showed limited discriminatory capacity in Aβ+, tau+, and apolipoprotein E ε4 (APOE ε4) carrier groups. Furthermore, CSF NDRG2 levels were positively correlated with GAP-43, a marker of synaptic plasticity. Conclusions The present study demonstrates that NDRG2 is a potential biomarker for non-AD derived MCI and suggests its involvement in synaptic plasticity impairment.
Higher p62/SQSTM1 levels were associated with tau pathology and an elevated risk of AD, and Tau-related pathological changes and brain structural alterations might be involved in the relationship between the p62/SQSTM1-related autophagy processes and cognition.
Ming-Yan Yao, Hai-Hua Guo, Qiong-Yao Li et al.· Journal of Alzheimer's Disea...· 0 citations
Reliable blood-based biomarkers are increasingly needed for the detection and monitoring of Alzheimer’s disease (AD). Left–right determination factor 2 (LEFTY2) is a secreted protein of the transforming growth factor-β (TGF-β) superfamily. Evidence from AD-related neuronal models suggests that LEFTY2 promotes neuronal...
Wu-Li Wei, Raymond Y. Lo, H. Harn et al.· Frontiers in Aging Neuroscie...· 0 citations
Background Neurofilament proteins are fluid biomarkers of neuroaxonal damage in various neurological diseases. However, it remains to be elucidated whether CSF neurofilament heavy (NfH) protein levels correlate with cognitive decline and progression in Alzheimer’s disease (AD). Methods This study included 165 cognitive...
Jian-Jing Zhang, Xi-Wu Wang, Ling-Kai Yang et al.· Frontiers in Aging Neuroscie...· 0 citations
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease primarily affecting motor neurons but also frequently involving cognitive impairment. Cerebrospinal fluid (CSF) measurements of {beta} amyloid peptides (A{beta}40, A{beta}42), tau proteins, and neurofilaments are clinically established biomarkers in neu...
F. Eberle, S. Bersen, F. Rachel et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.